PurMinds NeuroPharma

Neuro Drug Discovery

PUR001B Clin0 brain injury, neurodegenerative diseases; PUR002 Clin0 stroke, Parkinson's

PurMinds NeuroPharma is developing disease-modifying therapeutics for neurological conditions. Psychedelic compounds have a bad reputation, however they offer much potential for treating neurological conditions due to their neuroplasticity effects. PurMinds owns and operates a portfolio of assets and licenses enabling them to produce, sell and export psychedelic compounds including psilocybin, MDMA, LSD and DMT. Using their PurPrecision practice, PurMinds is using a data-driven approach to validate therapeutics and stratify patient recruitment in clinical trials. PurMinds lead candidate, PUR101, is a botanical psilocybin formulation that is going through preclinical stages to treat patients with depression in neurological disorders.